Celladon Corp Share Price Nasdaq
Equities
US15117E1073
Biotechnology & Medical Research
Sales 2024 * | 25.22M 1.98B | Sales 2025 * | 32.65M 2.57B | Capitalization | 3.36M 265M |
---|---|---|---|---|---|
Net income 2024 * | -24M -1.89B | Net income 2025 * | -9M -708M | EV / Sales 2024 * | 0.13 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.1 x |
P/E ratio 2024 * |
-0.15
x | P/E ratio 2025 * |
-0.63
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
Latest transcript on Celladon Corp
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 13/06/17 |
James Vollins
CMP | Compliance Officer | 55 | 12/04/23 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 17/07/22 | |
Thomas Dietz
CHM | Chairman | 60 | 21/03/16 |
David Apelian
CEO | Chief Executive Officer | 59 | 13/06/17 |
1st Jan change | Capi. | |
---|---|---|
+41.79% | 54.04B | |
+45.60% | 41.96B | |
-0.56% | 41.92B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+29.60% | 12.28B | |
+24.91% | 12.19B |